Premium
Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system
Author(s) -
Sirohi Bhawna,
Powles Ray,
Mehta Jayesh,
Raje Noopur,
Kulkarni Samar,
Ramiah Veshana,
Saso Radovan,
Horton Clive,
Bhagwati Niyati,
Singhal Seema,
Treleaven Jennifer
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01744.x
Subject(s) - medicine , multiple myeloma , gastroenterology , bence jones protein , progressive disease , chemotherapy , clinical endpoint , surgery , immunology , antibody , randomized controlled trial , immunoglobulin light chain
Because the presence of IgG paraprotein in the blood is clear cut, it makes IgG myeloma a more circumscribed disease than myeloma as a whole in which to study treatment efficacy, particularly relating to complete remission (CR). Between May 1989 and December 1997, 177 consecutive patients with IgG myeloma who were <75 years old were seen, of whom 153 entered a sequential therapy (ST) programme of initial courses of C‐VAMP infusional chemotherapy (IC), high‐dose treatment (with or without stem cell rescue) (119 patients) and maintenance interferon (87 patients). 74/153 (48.4%) patients entered CR. Median overall survival (OS) and event‐free survival (EFS) were 4.9 and 2.1 years, respectively. Multivariate analysis at presentation showed OS was significantly prolonged for β 2 M <2.7 mg/l and age 8.5 g/dl predicted for longer EFS. For CR patients, age